OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
809559

Astena Holdings Co Ltd

PharmaceuticalsVerified

Astena Holdings Co Ltd maintains a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.24, suggesting it can cover its short-term liabilities but with limited buffer. The company's cash and equivalents amount to 10,190,000,000 JPY, which is less than its long-term debt of 22,649,000,000 JPY, resulting in a net cash position that is negative after subtracting total debt. In terms of profitability, Astena Holdings Co Ltd reports a return on equity (ROE) of 8.07% and a return on assets (ROA) of 2.9%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is generating returns, but not at a level that would be considered exceptional. The operating income of 2,837,000,000 JPY and net income of 218,600,000 JPY further support the notion that the company is profitable, but not highly so. Astena Holdings Co Ltd operates through four business segments: Fine Chemicals, Medical, Health & Beauty Care (HBC) and Food, and Industrial Chemicals. The Fine Chemicals segment is engaged in the manufacture and sale of pharmaceutical raw materials and pharmaceuticals. The Medical segment is engaged in the manufacturing and sales of pharmaceutical products. The HBC and Food segment is engaged in the manufacture and sale of cosmetic raw materials, functional food raw materials, general use medicines, and related products, as well as cosmetics. The Industrial Chemicals segment manufactures and sells chemicals for electronic industries, surface treatment chemicals, chemical products, surface treatment chemical raw materials, and to printed circuit board and other manufacturing plants. The company's growth trajectory is reflected in its recent financial performance. The operating cash flow of 3,393,000,000 JPY and free cash flow of 696,000,000 JPY indicate that the company is generating positive cash flows from operations. However, the capital expenditure of -3,175,000,000 JPY suggests that the company is investing in its operations, which could be a sign of growth or expansion. The revenue of 62,744,000,000 JPY and gross profit of 21,867,000,000 JPY indicate that the company is generating significant revenue and profit, but the exact growth rate is not provided. The risk assessment for Astena Holdings Co Ltd indicates a medium liquidity risk and a low dilution risk. The key flags include the fact that the company's net cash is negative after subtracting total debt, which could be a concern for liquidity. The dilution risk is low, suggesting that the company is not expected to issue a significant amount of new shares in the near future. The company's capital structure and liquidity position are important factors to consider when assessing its financial health. Recent events related to Astena Holdings Co Ltd include the latest actual EPS of 54.23 JPY and the latest actual revenue of 62,744,000,000 JPY. These figures are based on analyst estimates and provide insight into the company's recent performance. The company's financial performance is in line with its reported revenue and net income, indicating that it is meeting or exceeding expectations.

30-day price · 8095+8.00 (+1.7%)
Low$466.00High$497.00Close$480.00As of16 May, 00:00 UTC
Profile
CompanyAstena Holdings Co Ltd
Ticker8095.T
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Astena Holdings Co Ltd operates in the pharmaceuticals and fine chemicals industry, generating revenue through the manufacture and sale of pharmaceutical raw materials, pharmaceutical products, cosmetic and food raw materials, and industrial chemicals.

Classification. Astena Holdings Co Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.

Astena Holdings Co Ltd maintains a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.24, suggesting it can cover its short-term liabilities but with limited buffer. The company's cash and equivalents amount to 10,190,000,000 JPY, which is less than its long-term debt of 22,649,000,000 JPY, resulting in a net cash position that is negative after subtracting total debt. In terms of profitability, Astena Holdings Co Ltd reports a return on equity (ROE) of 8.07% and a return on assets (ROA) of 2.9%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is generating returns, but not at a level that would be considered exceptional. The operating income of 2,837,000,000 JPY and net income of 218,600,000 JPY further support the notion that the company is profitable, but not highly so. Astena Holdings Co Ltd operates through four business segments: Fine Chemicals, Medical, Health & Beauty Care (HBC) and Food, and Industrial Chemicals. The Fine Chemicals segment is engaged in the manufacture and sale of pharmaceutical raw materials and pharmaceuticals. The Medical segment is engaged in the manufacturing and sales of pharmaceutical products. The HBC and Food segment is engaged in the manufacture and sale of cosmetic raw materials, functional food raw materials, general use medicines, and related products, as well as cosmetics. The Industrial Chemicals segment manufactures and sells chemicals for electronic industries, surface treatment chemicals, chemical products, surface treatment chemical raw materials, and to printed circuit board and other manufacturing plants. The company's growth trajectory is reflected in its recent financial performance. The operating cash flow of 3,393,000,000 JPY and free cash flow of 696,000,000 JPY indicate that the company is generating positive cash flows from operations. However, the capital expenditure of -3,175,000,000 JPY suggests that the company is investing in its operations, which could be a sign of growth or expansion. The revenue of 62,744,000,000 JPY and gross profit of 21,867,000,000 JPY indicate that the company is generating significant revenue and profit, but the exact growth rate is not provided. The risk assessment for Astena Holdings Co Ltd indicates a medium liquidity risk and a low dilution risk. The key flags include the fact that the company's net cash is negative after subtracting total debt, which could be a concern for liquidity. The dilution risk is low, suggesting that the company is not expected to issue a significant amount of new shares in the near future. The company's capital structure and liquidity position are important factors to consider when assessing its financial health. Recent events related to Astena Holdings Co Ltd include the latest actual EPS of 54.23 JPY and the latest actual revenue of 62,744,000,000 JPY. These figures are based on analyst estimates and provide insight into the company's recent performance. The company's financial performance is in line with its reported revenue and net income, indicating that it is meeting or exceeding expectations.
Key takeaways
  • Astena Holdings Co Ltd has a moderate debt-to-equity ratio of 0.84, indicating a balanced capital structure.
  • The company's return on equity of 8.07% and return on assets of 2.9% suggest it is profitable but not highly so.
  • The company operates through four business segments, with a focus on pharmaceuticals, fine chemicals, and industrial chemicals.
  • The company's liquidity position is characterized as medium, with a current ratio of 1.24.
  • The company's net cash is negative after subtracting total debt, which could be a concern for liquidity.
  • The company's recent financial performance, including an operating cash flow of 3,393,000,000 JPY and free cash flow of 696,000,000 JPY, indicates positive cash generation.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$62.74B
Gross profit$21.87B
Operating income$2.84B
Net income$2.19B
R&D
SG&A
D&A
SBC
Operating cash flow$3.39B
CapEx-$3.17B
Free cash flow$696.0M
Total assets$75.44B
Total liabilities$48.37B
Total equity$27.08B
Cash & equivalents$10.19B
Long-term debt$22.65B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$27.08B
Net cash-$12.46B
Current ratio1.2
Debt/Equity0.8
ROA2.9%
ROE8.1%
Cash conversion1.6%
CapEx/Revenue-5.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric8095Activity
Op margin4.5%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin3.5%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin34.9%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-5.1%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity84.0%71.3% medp25 19.0% · p75 91.7%above median
Observations
IR observations
Last actual EPS54.23 JPY
Last actual revenue62,744,000,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 14:07 UTC#7ecdd78f
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 14:10 UTCJob: b512422c